Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 25, 2022, Rani Therapeutics Holdings, Inc. (the "Company") held its annual meeting of stockholders ("Annual Meeting"). As of March 30, 2022, the record date for the Annual Meeting, there were 24,387,030 shares of Class A common stock outstanding and entitled to vote and 24,773,286 shares of Class B common stock outstanding and entitled to vote at the Annual Meeting. Holders of the Company's Class A common stock are entitled to one vote per share and holders of the Company's Class B common stock are entitled to ten votes per share. Holders of Class A common stock and Class B common stock voted together as a single class on all matters submitted to a vote of stockholders at the Annual Meeting.

The following is a summary of the matters voted on at the Annual Meeting based on the report of the voting results by the inspector of election. The Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 13, 2022 contains a description of the following proposals considered at the Annual Meeting, each of which were approved by the Company's stockholders at the Annual Meeting as set forth below:

1. The Company's stockholders elected by a majority of votes cast the director nominees below, to hold office until the 2023 annual meeting of stockholders or until their successors are duly elected and qualified, as follows:



                                               Broker
                         For       Withheld   Non-Voted
Talat Imran          236,209,213   130,136    2,702,155
Mir Imran            236,182,478   156,871    2,702,155
Dennis Ausiello      236,209,217   130,132    2,702,155
Lyn Baranowski       236,321,656    17,693    2,702,155
Jean-Luc Butel       236,208,740   130,609    2,702,155
Laureen DeBuono      236,209,217   130,132    2,702,155
Andrew Farquharson   236,184,417   154,932    2,702,155
Malik Nanavaty       236,209,217   130,132    2,702,155
Lisa Rometty         236,321,656    17,693    2,702,155

2. The Company's stockholders ratified the appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022, as follows:



For:         239,007,220
Against:          27,533
Abstain:           6,751

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses